Corcept医疗(CORT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CORT Corcept医疗

休市中 06-12 16:00:00 EDT

82.91

-0.34

-0.41%

盘后82.91

+0.000.00%

19:50 EDT

最高84.79	最低82.40	成交量71.91万
今开82.91	昨收83.25	日振幅2.87%
总市值89.01亿	流通市值72.03亿	总股本1.07亿
成交额5,995万	换手率0.83%	流通股本8,688万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept医疗","latestPrice":82.91,"timestamp":1781294400000,"preClose":83.25,"halted":0,"volume":719110,"hourTrading":{"tag":"盘后","latestPrice":82.91,"preClose":82.91,"latestTime":"19:50 EDT","volume":2760,"amount":228858.52,"timestamp":1781308243262,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.004084084084084125,"floatShares":86875270,"shares":107356686,"eps":0.35,"marketStatus":"休市中","change":-0.34,"latestTime":"06-12 16:00:00 EDT","open":82.91,"high":84.79,"low":82.404,"amount":59951204.01353999,"amplitude":0.028661,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.35,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":83.25,"preHourTrading":{"tag":"盘前","latestPrice":83.3,"preClose":83.25,"latestTime":"09:14 EDT","volume":163,"amount":13647.73572,"timestamp":1781270065168,"change":0.05,"changeRate":0.000601,"amplitude":0.024865},"postHourTrading":{"tag":"盘后","latestPrice":82.91,"preClose":82.91,"latestTime":"19:50 EDT","volume":2760,"amount":228858.52,"timestamp":1781308243262,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6860097550389503,"impliedVol":0.5183,"impliedVolPercentile":0.3705},"requestUrl":"/m/hq/s/CORT","defaultTab":"news","newsList":[{"id":"1157411460","title":"Corcept医疗曾于2021年11月收到司法部关于Korlym销售与推广的记录传票——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1157411460","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157411460?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:05","pubTimestamp":1780488322,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件披露，Corcept医疗公司曾在2021年11月收到美国司法部发出的记录传票，内容涉及该公司旗下药物Korlym的销售与推广活动。\n这一信息揭示了监管机构此前已对Corcept医疗的业务操作展开过调查。传票要求公司提供与Korlym相关的特定记录，表明司法部当时正在审查该药物的市场营销行为。\nKorlym是Corcept医疗的核心产品，用于治疗内源性库欣综合征。此次披露的传票事件，发生在近期其他监管动态之前，为理解该公司面临的整体监管环境提供了更多背景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1559883803.SGD","CORT","LU0566484027.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176930516","title":"美国司法部、加州保险局及原告各州决定不介入针对Corcept医疗的诉讼——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1176930516","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176930516?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:05","pubTimestamp":1780488319,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）的一份文件披露，美国司法部、加利福尼亚州保险局以及作为原告的多个州，已决定不介入针对Corcept医疗（Corcept Therapeutics）提起的相关诉讼。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4007","CORT","LU0566484027.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125500114","title":"Corcept医疗将重新提交新药申请，寻求Relacorilant用于库欣综合征治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1125500114","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125500114?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:00","pubTimestamp":1779883242,"startTime":"0","endTime":"0","summary":"Corcept医疗宣布，将就其药物Relacorilant用于治疗库欣综合征患者的新药申请进行重新提交。此举旨在应对监管机构的反馈，并推动该疗法获得批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4532","LU1559883803.SGD","LU0566484027.USD","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136026732","title":"异动解读 | Piper Sandler上调目标价，Corcept医疗盘中大涨5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136026732","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136026732?lang=zh_cn&edition=full","pubTime":"2026-05-01 22:05","pubTimestamp":1777644341,"startTime":"0","endTime":"0","summary":"Corcept医疗（CORT）今日盘中股价大幅上涨5.33%，引起了市场关注。消息面上，根据路透社报道，华尔街券商Piper Sandler将Corcept Therapeutics Inc的目标价从73美元上调至88美元。分析师上调目标价通常被视为对公司未来前景的积极信号，可能增强了投资者信心，从而推动了股价上涨。该股在交易时段内表现强劲，反映出市场对此次分析师评级调整的积极反应。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180318588","title":"Corcept医疗将公布第一季度财报 同步举行企业进展说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1180318588","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180318588?lang=zh_cn&edition=full","pubTime":"2026-04-24 04:07","pubTimestamp":1776974822,"startTime":"0","endTime":"0","summary":"Corcept医疗（CORT）即将发布2024年第一季度财务业绩报告，届时公司将披露最新经营动态，并通过电话会议与投资者深度交流。此次会议将涵盖财务数据解读、研发管线进展及战略规划等关键议题，为市场提供全面评估企业价值的重要窗口。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT","BK4007","LU1559883803.SGD","LU0566484027.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184877931","title":"Corcept在SGO重磅会议公布Rosella关键试验完整数据：《柳叶刀》同步发表Lifyorli™联合白蛋白紫杉醇显著延长铂耐药卵巢癌患者总生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1184877931","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184877931?lang=zh_cn&edition=full","pubTime":"2026-04-11 04:46","pubTimestamp":1775853973,"startTime":"0","endTime":"0","summary":"Corcept医疗（Corcept Therapeutics）于美国妇科肿瘤学会（SGO）年会重磅环节公布了其关键性Rosella试验的完整数据，同时国际顶级医学期刊《柳叶刀》同步发表了相关研究成果。研究证实，其创新药物Lifyorli™（relacorilant）联合白蛋白紫杉醇治疗方案，能够显著改善铂类药物耐药性卵巢癌患者的总生存期。\n这一突破性进展为缺乏有效治疗手段的铂耐药卵巢癌患者提供了新的希望，也彰显了靶向皮质醇调节疗法在肿瘤治疗领域的应用潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1559883803.SGD","CORT","BK4532","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153014349","title":"FDA批准Corcept医疗选择性糖皮质激素受体拮抗剂Lifyorli™（Relacorilant）联合白蛋白紫杉醇用于铂耐药卵巢癌患者治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1153014349","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153014349?lang=zh_cn&edition=full","pubTime":"2026-03-26 00:45","pubTimestamp":1774457116,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已正式批准Corcept医疗公司研发的选择性糖皮质激素受体拮抗剂Lifyorli与白蛋白紫杉醇联合用药方案，用于治疗铂类耐药卵巢癌患者。这一重大进展为面临治疗困境的患者提供了新的希望。Lifyorli通过精准阻断糖皮质激素受体的活性，有效抑制肿瘤对化疗药物的耐药机制。与白蛋白紫杉醇的协同使用，有望显著提升晚期卵巢癌患者的临床应答率。此次批准标志着靶向激素通路治疗卵巢癌领域的突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4532","LU0566484027.USD","CORT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135304921","title":"FDA批准Relacorilant联合白蛋白紫杉醇治疗铂耐药上皮性卵巢癌、输卵管癌或原发性腹膜癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1135304921","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135304921?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:36","pubTimestamp":1774449374,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式批准Relacorilant与白蛋白紫杉醇（Nab-Paclitaxel）联合用药方案，用于治疗铂类药物耐药的上皮性卵巢癌、输卵管癌或原发性腹膜癌患者。这一重大监管进展为面临有限治疗选择的晚期妇科癌症患者提供了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT","BK4007","LU0566484027.USD","BK4532","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144431709","title":"Corcept医疗公布2025年第四季度及全年审计财报 同步披露公司运营进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1144431709","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144431709?lang=zh_cn&edition=full","pubTime":"2026-02-25 05:07","pubTimestamp":1771967265,"startTime":"0","endTime":"0","summary":"Corcept医疗（股票代码：CORT）今日正式发布2025年第四季度及全年经审计的财务业绩报告，同时就公司最新运营动态向市场作出全面通报。\n本次披露的财报数据涵盖关键经营指标，具体细节将于公告中详细呈现。公司管理层强调，此次审计结果将为企业战略部署及未来业务拓展提供重要依据。\n伴随财务数据的公布，Corcept医疗还同步更新了研发管线推进、临床实验进展及商业化布局等核心运营信息，展现出企业在创新药物领域的持续深耕与战略执行力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","LU0566484027.USD","BK4532","CORT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160444782","title":"Corcept医疗将公布2025年第四季度及全年财报，举行企业进展说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1160444782","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160444782?lang=zh_cn&edition=full","pubTime":"2026-02-18 05:06","pubTimestamp":1771362370,"startTime":"0","endTime":"0","summary":"Corcept医疗（股票代码：CORT）宣布，将于近期披露2025年第四季度及全年财务业绩。公司管理层将同步召开电话会议，详解阶段性经营成果与战略布局。此次会议将面向投资者开放问答环节，为市场提供直接沟通渠道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4007","CORT","LU0566484027.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609412465","title":"Corcept医疗盘中异动 股价大涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609412465","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609412465?lang=zh_cn&edition=full","pubTime":"2026-02-07 03:58","pubTimestamp":1770407886,"startTime":"0","endTime":"0","summary":"北京时间2026年02月07日03时58分，Corcept医疗股票出现异动，股价急速上涨5.16%。截至发稿，该股报40.34美元/股，成交量55.3895万股，换手率0.53%，振幅4.42%。Corcept医疗股票所在的生物技术行业中，整体涨幅为1.48%。Corcept医疗公司简介：Corcept Therapeutics Inc是一家商业阶段的制药公司，致力于通过调节激素皮质醇的作用来发现和开发治疗严重代谢、肿瘤和神经精神疾病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207035807a6dcc1f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207035807a6dcc1f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4532","CORT","LU0566484027.USD","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608825925","title":"Corcept医疗盘中异动 早盘急速拉升5.07%报41.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608825925","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608825925?lang=zh_cn&edition=full","pubTime":"2026-02-02 23:02","pubTimestamp":1770044561,"startTime":"0","endTime":"0","summary":"北京时间2026年02月02日23时02分，Corcept医疗股票出现异动，股价急速上涨5.07%。截至发稿，该股报41.89美元/股，成交量17.5786万股，换手率0.17%，振幅5.27%。Corcept医疗股票所在的生物技术行业中，整体涨幅为0.66%。Corcept医疗公司简介：Corcept Therapeutics Inc是一家商业阶段的制药公司，致力于通过调节激素皮质醇的作用来发现和开发治疗严重代谢、肿瘤和神经精神疾病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020223024197a48786&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020223024197a48786&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0566484027.USD","LU1559883803.SGD","BK4007","BK4532","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605144571","title":"Corcept医疗(CORT.US)抗癌小分子关键3期结果公布 有望明年上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2605144571","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605144571?lang=zh_cn&edition=full","pubTime":"2026-01-23 07:46","pubTimestamp":1769125597,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Corcept医疗宣布，其关键性3期临床试验ROSELLA达到总生存期这一主要终点。此前，美国FDA已受理relacorilant用于治疗铂耐药卵巢癌的上市申请，并设定PDUFA日期为2026年7月11日。接受relacorilant治疗患者的中位OS为16.0个月，而单用白蛋白紫杉醇患者的中位OS为11.9个月，两者相差4.1个月。Corcept正在推进relacorilant在卵巢癌及多种其他严重疾病中的开发，包括内源性高皮质醇症以及子宫内膜癌、宫颈癌、胰腺癌和前列腺癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Corcept医疗(CORT.US)抗癌小分子关键3期结果公布 有望明年上市","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","LU0566484027.USD","BK4532","CORT","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129226635","title":"Corcept医疗实验性卵巢癌药物达晚期试验主要目标 盘前股价飙升34.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129226635","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129226635?lang=zh_cn&edition=full","pubTime":"2026-01-22 21:26","pubTimestamp":1769088392,"startTime":"0","endTime":"0","summary":"在其实验性卵巢癌治疗药物成功达成晚期临床试验主要目标后，Corcept医疗（CORT）股价于盘前交易时段强势攀升34.82%。这一重大突破点燃了市场对该公司新药前景的强烈预期。\n该药物的积极数据不仅验证了其临床疗效，也为公司未来的商业化道路铺平了基石。投资者信心受到显著提振，推动股价出现大幅跃升，反映出市场对创新疗法商业价值的重新评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0566484027.USD","BK4007","CORT","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149619472","title":"Corcept医疗III期关键试验Rosella达到总生存期主要终点：Relacorilant治疗铂耐药卵巢癌显成效","url":"https://stock-news.laohu8.com/highlight/detail?id=1149619472","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149619472?lang=zh_cn&edition=full","pubTime":"2026-01-22 21:04","pubTimestamp":1769087068,"startTime":"0","endTime":"0","summary":"Corcept医疗（Corcept Therapeutics）宣布，其在研药物Relacorilant用于治疗铂耐药卵巢癌患者的III期关键临床试验Rosella，已成功达到总生存期（OS）这一主要终点。\n该研究结果标志着Relacorilant在延长患者生存时间方面展现出显著疗效，为铂耐药卵巢癌这一难治性疾病的治疗提供了新的希望。研究详细数据将在未来的医学会议上公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT","BK4007","LU0566484027.USD","BK4532","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170019706","title":"美国FDA拒绝批准Corcept Therapeutics治疗罕见激素紊乱症的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1170019706","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170019706?lang=zh_cn&edition=full","pubTime":"2025-12-31 23:10","pubTimestamp":1767193849,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局周三拒绝批准Corcept Therapeutics 治疗一种罕见激素紊乱症的药物，受此影响，这家制药商的股价暴跌逾50%。Corcept公司原计划将relacorilant用于治疗继发于皮质醇增多症的高血压患者。Corcept提交的试验数据显示，relacorilant能全面改善皮质醇增多症的各类体征和症状。Corcept公司还在研究该药物治疗卵巢癌、前列腺癌等多种严重疾病的潜力。该公司另一款已获批药物Korlym，用于治疗内源性库欣综合征成人患者因皮质醇增多症引发的高血糖。","market":"us","thumbnail":"https://community-static.tradeup.com/news/1b029fb1c966a80d0d154996a1b5e1e5","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/1b029fb1c966a80d0d154996a1b5e1e5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9e90ab36df29de2b226d0a3b3c0d142","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"美国FDA拒绝批准Corcept Therapeutics治疗罕见激素紊乱症的药物","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2595770534","title":"美股异动 | 新药申请未获FDA批准 Corcep医疗(CORT.US)暴跌超46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595770534","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595770534?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:50","pubTimestamp":1767192631,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，Corcep医疗股价暴跌超46%，报37.33美元。消息面上，该公司表示已收到美国食品药品监督管理局发出的完整回应函，其新药申请未获批准。该申请旨在寻求批准口服药物Relacorilant用于治疗因皮质醇增多症引发的继发性高血压。公司称，FDA在回应函中确认，Corcept的关键性GRACE临床试验达成主要终点，且GRADIENT试验数据具有验证性意义；但监管机构认为，现有资料仍不足以支持对该疗法作出有利的收益—风险评估，因而要求补充更多有效性证据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9e90ab36df29de2b226d0a3b3c0d142","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159891","BK4532","LU1559883803.SGD","CORT","LU0566484027.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128768697","title":"Corcept医疗的高皮质醇症销售前景被视为不切实际 -- 市场动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1128768697","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128768697?lang=zh_cn&edition=full","pubTime":"2025-12-17 03:56","pubTimestamp":1765914994,"startTime":"0","endTime":"0","summary":"1454 ET - UBS 分析师在一份报告中表示，Corcept医疗不太可能实现其对高皮质醇症治疗产品的销售预期。针对 Corcept 现有的高皮质醇症产品 Korlym 以及正在等待 FDA 批准的 relacorilant，他们预测至 2030 年高皮质醇症患者的销售额大约为 14 亿美元，远低于公司 30 亿至 50 亿美元的预期。要实现这一目标，Corcept 需扩大其分销能力，并希望医生的行为能够持续改变以及 Korlym 转向 relacorilant 的转化率几乎达到全面，并迅速被接受——分析师表示这一结果不太可能出现。该公司股票下跌 9.5%，报79.01美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","BK4007","CORT","BK4532","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517986458","title":"Corcept医疗盘中异动 股价大跌5.05%报56.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517986458","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517986458?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:50","pubTimestamp":1741121452,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时50分，Corcept医疗股票出现异动，股价大幅下跌5.05%。截至发稿，该股报56.09美元/股，成交量149.598万股，换手率1.42%，振幅6.96%。Corcept医疗股票所在的生物技术行业中，整体跌幅为0.16%。Corcept医疗公司简介：Corcept Therapeutics Inc是一家商业阶段的制药公司，致力于通过调节激素皮质醇的作用来发现和开发治疗严重代谢、肿瘤和神经精神疾病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305045053abe85a69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305045053abe85a69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CORT","LU0566484027.USD","BK4007","BK4532","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516202548","title":"Corcept医疗2024财年实现净利润1.40亿美元，同比增加33.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516202548","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516202548?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931284,"startTime":"0","endTime":"0","summary":"3月3日，Corcept医疗公布财报，公告显示公司2024财年净利润为1.40亿美元，同比增加33.33%；其中营业收入为6.75亿美元，同比增加40.04%，每股基本收益为1.35美元。从资产负债表来看，Corcept医疗总负债1.61亿美元，其中短期债务829000.00美元，资产负债比为5.23，流动比率为3.35。机构评级：截至2025年3月3日，当前有4家机构对Corcept医疗目标价做出预测，其中目标均价为99.75美元，其中最低目标价为76.00美元，最高目标价为130.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000210abe4acf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000210abe4acf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":0.1417},{"period":"1month","weight":0.4525},{"period":"3month","weight":1.5788},{"period":"6month","weight":-0.0577},{"period":"1year","weight":0.1648},{"period":"ytd","weight":1.3825}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Corcept Therapeutics Incorporated于1998年5月13日在特拉华州注册成立。该公司是一家商业阶段公司，从事发现和开发药物，通过调节激素皮质醇的作用来治疗严重的内分泌、肿瘤、代谢和神经系统疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.022337},{"month":2,"riseRate":0.409091,"avgChangeRate":0.008661},{"month":3,"riseRate":0.772727,"avgChangeRate":0.140734},{"month":4,"riseRate":0.545455,"avgChangeRate":0.005665},{"month":5,"riseRate":0.521739,"avgChangeRate":0.028192},{"month":6,"riseRate":0.478261,"avgChangeRate":0.045795},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.006529},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.006283},{"month":9,"riseRate":0.454545,"avgChangeRate":0.062175},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005789},{"month":11,"riseRate":0.5,"avgChangeRate":0.018834},{"month":12,"riseRate":0.409091,"avgChangeRate":0.027449}],"exchange":"NASDAQ","name":"Corcept医疗","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept医疗(CORT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Corcept医疗(CORT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Corcept医疗,CORT,Corcept医疗股票,Corcept医疗股票老虎,Corcept医疗股票老虎国际,Corcept医疗行情,Corcept医疗股票行情,Corcept医疗股价,Corcept医疗股市,Corcept医疗股票价格,Corcept医疗股票交易,Corcept医疗股票购买,Corcept医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept医疗(CORT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Corcept医疗(CORT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}